Nia Therapeutics Wins First FDA Breakthrough Designation for a Brain Implant That Treats Memory Loss After Traumatic Brain Injury
The FDA granted Breakthrough Device Designation to Nia Therapeutics' 60-channel Smart Neurostimulation System, a closed-loop brain implant that uses machine learning to detect impaired memory encoding and deliver targeted stimulation, marking the first such designation for TBI-related memory loss.
Overview
The U.S. Food and Drug Administration has granted Breakthrough Device Designation to Nia Therapeutics’ Smart Neurostimulation System (SNS) for the treatment of episodic memory loss in adults with prior moderate-to-severe traumatic brain injury, according to a BusinessWire press release published on March 13, 2026. The SNS is the first device to receive Breakthrough designation for TBI-related memory loss, an indication for which no FDA-cleared or approved therapies currently exist.
The Boston-area company, headquartered in Allston, Massachusetts, plans to file an Investigational Device Exemption application later this year to support the initiation of a first-in-human early feasibility study, according to the same announcement.
How the Device Works
The SNS is a fully implantable, wireless neuromodulation platform that records neural activity from 60 channels spanning four brain regions, according to the BusinessWire press release. That channel count represents an order-of-magnitude increase over commercially available neurostimulation devices: the NeuroPace RNS System, FDA-cleared for epilepsy, offers up to six channels, while Medtronic’s Percept adaptive deep brain stimulation system provides up to four, according to the same source.
Machine-learning classifiers, trained on each patient’s own neural signals, detect moments when memory encoding is impaired in real time. The device then delivers targeted electrical stimulation to the lateral temporal cortex. This closed-loop architecture distinguishes it from conventional deep brain stimulation systems, which deliver continuous or scheduled stimulation without adapting to the patient’s cognitive state.
“Memory can be improved by listening to the brain and stimulating at precisely the right moment,” said Michael J. Kahana, the company’s co-founder and CEO, in the BusinessWire announcement. Co-founder and President Daniel S. Rizzuto described the device as offering “an order of magnitude improvement over currently approved DBS devices.”
Clinical and Preclinical Evidence
In a randomized, sham-controlled study of neurosurgical patients with epilepsy and a history of moderate-to-severe TBI, the closed-loop stimulation approach improved recall by 19 percent, according to the BusinessWire press release. Randomly timed stimulation produced no benefit, underscoring the importance of precision timing.
The company also published preclinical validation results in the journal Brain Stimulation in January 2026, demonstrating the platform’s performance in three sheep models over a chronic implantation period, according to the BusinessWire announcement. Machine-learning classifiers distinguished movement from stillness with area-under-the-curve scores ranging from 0.92 to 0.98, with performance remaining stable throughout the implantation period. Systematic variation of stimulation parameters produced dose-dependent changes in alpha-band (8-12 Hz) and gamma-band (78-82 Hz) neural activity, and histological analyses showed no adverse tissue response.
The Unmet Need
More than 4.3 million Americans live with TBI-related disability, and no FDA-cleared or approved therapies currently address memory loss, according to the BusinessWire press release. The company states on its website that its broader mission is to transform treatment for the 27 million Americans living with memory loss.
The Breakthrough Device Designation provides Nia Therapeutics with prioritized review, increased interaction with FDA staff, and senior management involvement in future regulatory submissions.
What We Don’t Know
The 19 percent recall improvement was demonstrated in neurosurgical epilepsy patients with TBI history, not in a dedicated TBI population. Whether the same benefit will hold in a broader group of TBI patients with memory deficits remains to be tested in the planned first-in-human feasibility study.
The preclinical sheep study validated the device’s neural decoding and neuromodulation capabilities but did not test memory-specific outcomes in the animal model. The leap from demonstrating stable signal recording in sheep to restoring human memory function involves uncertainties that only clinical trials can resolve.
Nia Therapeutics has not disclosed the anticipated timeline, enrollment size, or clinical endpoints for its planned first-in-human study beyond stating that an IDE application is expected in 2026. The company’s funding status and financial runway to support clinical development have also not been publicly detailed.
Broader Context
The designation arrives as the brain-computer interface field enters a period of accelerating commercial momentum. As STAT News reported in its outlook for 2026, clinical trial participation across the BCI sector is expanding from single digits to dozens of patients, and multiple companies have moved beyond early feasibility studies after securing FDA Breakthrough Device Designations. The Nia Therapeutics announcement extends that momentum into cognitive restoration, a domain distinct from the movement and communication applications that have dominated BCI development to date.